VivoSim Labs Files 10-K/A, Confirms Smaller Reporting Status
Ticker: VIVS · Form: 10-K/A · Filed: Jul 29, 2025 · CIK: 1497253
| Field | Detail |
|---|---|
| Company | Vivosim Labs, Inc. (VIVS) |
| Form Type | 10-K/A |
| Filed Date | Jul 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K/A, SEC Filing, Smaller Reporting Company, Regulatory Compliance, Biotechnology, Nasdaq, Amendment
Related Tickers: VIVS
TL;DR
**VivoSim Labs' 10-K/A is a routine administrative update, confirming its smaller reporting status, which means no major financial news but highlights its ongoing compliance.**
AI Summary
VivoSim Labs, INC. (VIVS) filed a 10-K/A on July 29, 2025, for the fiscal year ended March 31, 2025, amending its annual report. The filing confirms VIVS is a non-accelerated filer and a smaller reporting company, indicating its market capitalization and revenue are below certain thresholds. The company's business address is 11555 Sorrento Valley Road, Suite 100, San Diego, CA 92121, and its telephone number is 858-224-1000. VIVS's common stock, with a par value of $0.001 per share, is traded on The Nasdaq Stock Market LLC under the symbol VIVS. The amendment confirms the company has filed all required reports under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and has been subject to such filing requirements for the past 90 days. It also states that VIVS has submitted every Interactive Data File required pursuant to Rule 405 of Regulation S-T during the preceding 12 months. The filing does not provide specific revenue or net income figures, but its status as a smaller reporting company suggests these figures are likely below the thresholds for larger filers. The primary purpose of this 10-K/A is to amend the original 10-K, likely for minor corrections or updates, rather than to announce major financial shifts.
Why It Matters
This 10-K/A filing from VivoSim Labs (VIVS) primarily serves to amend its annual report, confirming its status as a non-accelerated filer and a smaller reporting company. For investors, this status implies VIVS operates with fewer regulatory burdens compared to larger firms, but also suggests a smaller market footprint and potentially higher risk due to limited resources. Employees and customers are unlikely to see direct immediate impacts from this administrative filing, but the company's continued compliance with SEC regulations reinforces its operational stability. In a competitive landscape, VIVS's smaller reporting status means it competes against larger, more established biological products companies with greater financial and research capabilities, making its growth trajectory a key focus.
Risk Assessment
Risk Level: low — The risk level is low because this 10-K/A is an amendment to an annual report, primarily confirming administrative details like the company's filing status (non-accelerated filer, smaller reporting company) and compliance with SEC reporting requirements. It does not introduce new financial risks or significant operational changes. The filing explicitly states VIVS has filed all required reports and submitted all Interactive Data Files, indicating strong regulatory compliance.
Analyst Insight
Investors should view this 10-K/A as a routine compliance update, not a catalyst for immediate action. It reinforces VivoSim Labs' adherence to SEC regulations, which is a positive sign for corporate governance. However, investors should await the full 10-K for detailed financial performance and strategic insights before making investment decisions.
Key Numbers
- $0.001 — Common Stock Par Value (Par value per share of VIVS common stock, indicating a low nominal value.)
- 2025-03-31 — Fiscal Year End (The period of report for the 10-K/A, indicating the financial data covered.)
- 2025-07-29 — Filing Date (Date the 10-K/A was filed, showing the recency of the amendment.)
Key Players & Entities
- VivoSim Labs, INC. (company) — registrant filing the 10-K/A
- VIVS (company) — trading symbol for VivoSim Labs, INC.
- SEC (regulator) — Securities and Exchange Commission, requiring the filing
- The Nasdaq Stock Market LLC (company) — exchange where VIVS common stock is registered
- $0.001 (dollar_amount) — par value per share of common stock
- March 31, 2025 (date) — fiscal year end for the amended report
- July 29, 2025 (date) — filing date of the 10-K/A
- 11555 Sorrento Valley Road, Suite 100, San Diego, CA 92121 (location) — business address of VivoSim Labs, INC.
- 858-224-1000 (phone_number) — business phone number of VivoSim Labs, INC.
- 001-35996 (regulatory_id) — Commission File No. for VivoSim Labs, INC.
FAQ
What is the purpose of VivoSim Labs' 10-K/A filing?
The 10-K/A filing by VivoSim Labs (VIVS) is an amendment to its annual report for the fiscal year ended March 31, 2025. Its primary purpose is to update or correct information in the original 10-K, specifically confirming its status as a non-accelerated filer and a smaller reporting company, and affirming its compliance with SEC reporting requirements.
What does 'smaller reporting company' mean for VivoSim Labs?
For VivoSim Labs (VIVS), being a 'smaller reporting company' means it qualifies for certain scaled disclosure requirements under SEC regulations. This typically applies to companies with a public float of less than $250 million or annual revenues of less than $100 million, allowing for reduced reporting burdens compared to larger public companies.
Is VivoSim Labs (VIVS) compliant with SEC filing requirements?
Yes, the 10-K/A filing explicitly states that VivoSim Labs (VIVS) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and has been subject to such filing requirements for the past 90 days. It also confirms the submission of all required Interactive Data Files.
Where is VivoSim Labs (VIVS) common stock traded?
VivoSim Labs (VIVS) common stock, with a par value of $0.001 per share, is registered and traded on The Nasdaq Stock Market LLC under the trading symbol VIVS.
What is VivoSim Labs' (VIVS) business address and contact information?
VivoSim Labs, INC.'s business address is 11555 Sorrento Valley Road, Suite 100, San Diego, CA 92121. The company's telephone number is 858-224-1000.
Did the 10-K/A filing for VivoSim Labs (VIVS) include financial results?
The provided 10-K/A filing primarily focuses on administrative and compliance updates, such as confirming filing status. It does not explicitly detail specific revenue or net income figures for VivoSim Labs (VIVS), though its 'smaller reporting company' status implies these figures are below certain thresholds.
What was the fiscal year end for the VivoSim Labs (VIVS) 10-K/A?
The 10-K/A filing for VivoSim Labs (VIVS) is for the fiscal year ended March 31, 2025, as stated in the document.
What is the significance of VivoSim Labs (VIVS) being a 'non-accelerated filer'?
Being a 'non-accelerated filer' means VivoSim Labs (VIVS) has a public float of less than $75 million. This classification allows the company more time to file its annual and quarterly reports compared to accelerated or large accelerated filers, and it is exempt from certain internal control reporting requirements.
Are there any major risks highlighted in VivoSim Labs' (VIVS) 10-K/A?
The 10-K/A filing for VivoSim Labs (VIVS) is an administrative amendment and does not introduce new or significant risks. It primarily confirms compliance and filing status, suggesting no immediate new operational or financial risks are being disclosed through this specific document.
How does VivoSim Labs' (VIVS) filing status impact investors?
VivoSim Labs' (VIVS) status as a non-accelerated, smaller reporting company means it has fewer disclosure requirements than larger companies. While this can reduce administrative costs for VIVS, investors might have access to less detailed or less frequent information compared to investments in larger, more heavily regulated firms.
Industry Context
VivoSim Labs operates within the biological products sector, specifically focusing on areas that do not involve diagnostic substances. This industry is characterized by significant research and development investment, long product development cycles, and stringent regulatory oversight from bodies like the FDA. The competitive landscape often includes both large, established pharmaceutical and biotechnology companies, as well as smaller, specialized firms focused on niche therapeutic areas or novel technologies.
Regulatory Implications
As a company in the biological products industry, VivoSim Labs is subject to extensive regulatory scrutiny. Compliance with FDA regulations for product development, manufacturing, and marketing is paramount. The filing of a 10-K/A suggests adherence to SEC reporting requirements, but any future product development or commercialization efforts will face significant regulatory hurdles that could impact timelines and costs.
What Investors Should Do
- Review the original 10-K filing for details on the specific amendments made in the 10-K/A.
- Monitor future filings for updates on product development, clinical trials, and regulatory approvals.
- Assess the company's financial health and cash burn rate, given its status as a smaller reporting company.
Key Dates
- 2025-03-31: Fiscal Year End — Marks the end of the reporting period for the annual financial statements included in the 10-K/A.
- 2025-07-29: 10-K/A Filing Date — The date the amended annual report was filed with the SEC, indicating the recency of the disclosed information.
Glossary
- 10-K/A
- An amended annual report filed with the SEC to correct or update previously filed information. (This filing is an amendment to VivoSim Labs' original 10-K, suggesting a need for corrections or additions to the initial annual report.)
- Non-accelerated filer
- A company that does not meet the thresholds for accelerated or large accelerated filer status, typically based on market capitalization and filing history. (Indicates VivoSim Labs is a smaller company in terms of market size and public float.)
- Smaller reporting company
- A company that meets certain criteria for revenue and public float, allowing for scaled disclosure requirements. (Confirms VivoSim Labs has lower revenue and market capitalization compared to larger public companies.)
- Section 13 or 15(d) of the Securities Exchange Act of 1934
- Sections of the Exchange Act that mandate periodic reporting requirements for public companies. (Confirms VivoSim Labs is subject to ongoing reporting obligations, having filed all required reports in the preceding 12 months.)
- Regulation S-T Rule 405
- Requires companies to submit Interactive Data Files (XBRL) in accordance with specific formatting and submission rules. (Indicates VivoSim Labs has complied with electronic filing requirements for its financial data in the past year.)
Year-Over-Year Comparison
This filing is an amendment (10-K/A) to the original 10-K for the fiscal year ended March 31, 2025. As such, it does not represent a year-over-year comparison of financial metrics but rather a correction or update to the previously filed annual report. Investors should refer to the original 10-K and any subsequent filings to understand the company's performance trends and changes in its financial position and risk factors.
Filing Details
This Form 10-K/A (Form 10-K/A) was filed with the SEC on July 29, 2025 regarding VivoSim Labs, INC. (VIVS).